Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
and mortality rates in neonatal calves, without the use of enteric disease vaccines, by instituting proper sanitation and management practices. Conversely, vaccination programs for neonatal enteric disease are rarely successful in the absence of reasonably good sanitation and management because heavy exposure to causative agents can overwhelm vaccinal resistance and because of problems with cryptosporidiosis, salmonellosis, and other enteric infections for which vaccines are either not available or minimally effective. Vaccination programs are generally unsuccessful when calves are taken from their dams and raised on a milk replacer diet, which does not contain the antibodies that are found in the dam’s milk.11

REFERENCES

1. Woode GN, Bridger JC: Isolation of small viruses resembling astrovirus and caliciviruses from acute enteritis of calves. J Med Microbiol 11:441–452, 1978
2. Storz J, Leary JJ, Carlson JH, et al: Parvoviruses associated with diarrhea in calves. J Am Vet Med Assoc 173:624–627, 1978
3. Woode GN, Reed DE, Runnels PL, et al: Studies of an unclassified virus isolated from diarrheic calves. Vet Microbiol 7:221–240, 1982
4. Blood DC, Radostits OM, Henderson JA, et al: Acute undifferentiated diarrhea of newborn calves. In Blood RC, Radostits OM (ed): Veterinary Medicine, ed 6. London, Bailliere Tindall, 1983, pp 557–559
5. Snodgrass DR, Herring AJ, Campbell I, et al: Comparison of atypical rotaviruses from calves, piglets, lambs, and man. J Gen Virol 65:909–914, 1984
6. Mebus CA, Rhodes MB, Underdahl NR: Neonatal calf diarrhea caused by a virus that induces villous epithelial cell syncytia. Am J Vet Res 39:1223–1228, 1978
7. England JJ, Frye CS, Enright EA: Negative contrast electron microscopy diagnosis of viruses of neonatal calf diarrhea. Cornell Vet 66:172–182, 1976
8. Flewett TH: Electron microscopy in the diagnosis of infectious diarrhea. J Am Vet Med Assoc 173:538–543, 1978
9. Stockdale PHG, Niilo L: Production of coccidiosis with Eimeria zuernii. Can Vet J 17:35–37, 1976
10. Moon HW, McClurkin AW, Isaacson RE, et al: Pathogenic relationships of rotavirus, Escherichia coli, and other agents in mixed infections in calves. J Am Vet Med Assoc 173:577–583, 1978
11. Acres SD, Babiuk LA: Studies on rotaviral antibody in bovine serum and lacteal secretions using radioimmunoassay. J Am Vet Med Assoc 173:555–559, 1978

Rotavirus and Coronavirus Vaccines

Bovine rotaviruses and bovine coronavirus cause acute malabsorptive diarrheal disease, primarily in calves less than 3 weeks of age.1–3 Both agents attack the small intestinal villus enterocytes, causing their wholesale desquamation into the intestinal lumen.1,4 This is accompanied by a drastic reduction in the numbers and size of small intestinal villi.1,4 A malabsorption syndrome results from a reduction in surface area for absorption and from a lack of brush border disaccharidase enzymes.1,4 Affected calves have watery diarrhea and may become hypovolemic, dehydrated, hyponatremic, hypochloremic, acidicotic, and hyperkalemic.1
General Considerations

Considerable evidence is available to support a conclusion that neither of the two commercial bovine rotavirus-coronavirus vaccine products that are presently available in the United States is capable of providing effective control of bovine rotavirus (BRV) and bovine coronavirus infections in calves, under the constraints prevailing in most commercial cattle production systems. Two approaches have been used in an attempt to protect calves against BRV and coronavirus infections.

The first approach involves vaccination of neonatal calves with an MLV vaccine (Calf Guard, Norden Laboratories, Lincoln, NE 68521), administered by the oral route. The objective is to stimulate a cell-mediated immune response and local secretory IgM and IgA antibody production by the intestinal mucosa. Calves begin producing detectable levels of local secretory (intestinal) IgM antibodies within 4 to 6 days after successful oral vaccination. This is followed, within 2 to 6 more days, by the appearance of detectable levels of locally produced intestinal IgA antibodies. Calves are resistant to challenge from the initial appearance of local IgM antibodies.

In order to consistently elicit an effective immune response, the vaccine must be administered orally, immediately after birth, and before the calf has nursed. Ordinarily, this is practical only with dairy calves. Because the colostrum of most heifers and cows contains detectable levels of viral neutralizing antibodies, administration of colostrum should be delayed for several hours following vaccination, in order to avoid inactivation of vaccine virus. If the calf has nursed before it can be vaccinated, it is recommended that vaccination be delayed until 6 hours after nursing, and that the calf not be fed colostrum again until 6 hours after vaccine is administered.

It has been conclusively shown that Calf Guard is ineffective when a portion of the calves on a farm or ranch are left unvaccinated in double-blind vaccine evaluation studies. Apparently, the resistance induced by vaccination is easily overwhelmed by exposure to large amounts of virus shed by unvaccinated calves. However, when all calves were either vaccinated or not vaccinated in sequential comparisons, morbidity and mortality rates from neonatal enteric disease were significantly reduced by vaccination. Nonetheless, the design and statistical validity of these latter kinds of trials have been questioned.

Under practical conditions, in the experience of the author and others, this vaccination regimen has seldom resulted in dramatic improvements in calf health. Under commercial conditions, few owners or employees will administer vaccine within minutes after birth or effectively regulate the intake of colostrum in relation to the time of vaccination. Therefore, it is likely that many calves are exposed to infection before they can be vaccinated and that vaccine virus is often neutralized by ingested colostral antibodies. Consequently, it is likely that relatively few calves are actually immunized under commercial conditions.

The second approach involves intramuscular vaccination of preg-
nant cows with either MLV vaccine (Calf Guard, Norden Laboratories) or an inactivated viral vaccine (Scourguard 3 [K] Norden Laboratories), in order to ensure that high levels of specific viral neutralizing lactoglobulins will be present in the colostrum and in milk consumed by the calf during the first several days of life. Infectious viral particles are neutralized by these antibodies within the digestive tract of the calf, preventing infection of the intestinal villus enterocytes.\textsuperscript{1,8,15,16} Until recently it was believed that circulating passive humoral antibodies, absorbed from the gut of the calf during the first 24 hours of life, did not play an important role in immunity to bovine enteric rotaviral and coronaviral infections.\textsuperscript{1,4,7} It is now known, however, that passive humoral BRV antibodies of the IgG\textsubscript{1} class are transferred into the small intestinal lumen, where (in suitable concentrations) they protect against experimental challenge.\textsuperscript{16} In addition, vaccination of pregnant cows (at least with an experimental vaccine containing live rotavirus and water-in-oil adjuvant) results in production of antigen-specific transformation colostral lymphocytes. Ingestion of these sensitized colostral lymphocytes by 1-day-old calves confers partial protection against challenge with virulent BRV.\textsuperscript{8}

Colostrum, from most vaccinated cows and from some unvaccinated cows, is sufficiently high in virus-neutralizing (VN) antibodies that it is highly protective during the immediate period when it is being consumed by the calf.\textsuperscript{1,3,6-8,13,14,16,17} Since most calves become relatively resistant to the adverse clinical effects of BRV and coronavirus infections prior to reaching 3 to 4 weeks of age, these diseases are readily preventable in production systems in which it is feasible to hand-feed colostrum from vaccinated cows throughout the first 3 to 4 weeks of life.\textsuperscript{3,18} Even seronegative calves that do not receive colostral BRV antibodies within 24 hours after birth are solidly protected as long as they are fed colostrum or colostrum:milk mixtures that have a minimum BRV VN antibody titer of 1:1024 or higher.\textsuperscript{3,8,14,18} Colostrum or colostrum:milk mixtures having BRV VN antibody titers between 1:256 and 1:679 may be partially\textsuperscript{3,17-19} or completely protective,\textsuperscript{7} depending on (1) the size of the challenge dose of BRV, (2) the virulence of the challenge virus, (3) the degree of antigenic relatedness between the challenge virus and the immunizing virus, (4) the quality of calf management, and (5) the degree of exposure to other enteropathogens.\textsuperscript{4,20} Colostrum or colostrum:milk mixtures with BRV VN antibody titers of 1:44 or less are clearly nonprotective.\textsuperscript{14,17,18}

The major unresolved problem area, with respect to prevention of BRV and coronavirus infections by vaccination, is the suckling beef calf. Concentrations of BRV and coronavirus VN antibodies in the milk of vaccinated cows fall below protective levels by 3 to 7 days following parturition.\textsuperscript{1,2,14,15} Ideally, beef calves from vaccinated dams will develop subclinical enteric viral infections within the first few days after birth, while either milk VN antibody concentrations or (serum-derived) intestinal IgG\textsubscript{1} VN antibody concentrations are still partially protective.\textsuperscript{1,4,5,18} However, some calves may not be exposed to BRV and coronavirus until after milk antibody concentrations fall below protec-
tive levels. Other calves fail to mount an immune response to viral challenge while protected by lactogenic immunity and remain susceptible to a subsequent exposure. Finally, many calves exposed to BRV while protected by lactogenic immunity will begin to shed virus and manifest signs of mild enteric disease within 1 to 9 days after VN antibodies in milk have fallen to nonprotective levels. Unfortunately, in lieu of complete protection, the manifestations of passive immunity to BRV that are often noted are (1) a delay of a few days in the onset of clinical signs, and/or (2) reduced severity of clinical signs, and/or (3) a reduction in the length of the period of viral shedding associated with infection. Although there are reports of successful field trials involving BRV/BRV-coronavirus–vaccinated cows, negative results have also been reported.

One of the major shortcomings of Calf Guard is its relative inefficiency for boosting serum and colostral antibody titers of seropositive cows. The ranges in BRV VN colostral antibody titers that have been reported in nonvaccinated cows, Calf Guard-vaccinated cows, and Scourguard 3 (K)-vaccinated cows are 1:32 to 1:3200, 1:501 to 1:4395, and 1:2896, respectively (Table 24). Experimental vaccines utilizing live BRV, either in Freund's incomplete adjuvant or in water-in-oil emulsions of mineral oil containing mannide oleate, stimulate much higher BRV VN antibody titers than those obtained with present commercial vaccines (see Table 24). Vaccination with an experimental vaccine of this type resulted in concentrations of BRV VN antibodies in milk of 1:1680 at 30 days after parturition. This is above the levels regarded as being protective. This vaccine was administered by intramuscular injection 8 to 10 weeks before the anticipated calving date and readministered 2 weeks later by infusion into the involuted mammary glands.

At present, there is only one known serotype of bovine coronavirus. However, at least two serotypes of BRV are known to exist in the United States and Japan, and at least three BRV serotypes exist in Great Britain. Both passive and active immunity to BRV infections are serotype specific. Some serotypes of human rotavirus (HRV) are pathogenic for calves, and a high prevalence of serum VN antibodies to three different serotypes of HRV has been reported in British cattle.

Both of the bovine rotavirus-coronavirus vaccines that are commercially available in the United States (Calf Guard and Scourguard 3 [K], Norden Laboratories) are prepared utilizing (only) the original Nebraska calf diarrhea rotavirus isolate, which has been designated BRV-1. The implication of this for vaccinal efficacy is, as yet, unclear. Although BRV-1 is thought to be the most common serotype affecting cattle in the United States, some vaccine "breaks" have been found to have resulted from herd infections with heterologous virus. Vaccination with a BRV-1 vaccine of cows seropositive to BRV-1, BRV-2, HRV-1, HRV-2, and HRV-3 resulted in significant increases in serum VN antibody titers to all five agents. This indicates that effective monovalent vaccines could be useful for control of all BRV and HRV serotypes that are present in a herd at the time of booster vaccination.
Table 24. Effect of Maternal Vaccination with Various Kinds of Bovine Rotavirus Vaccines on Colostral Rotavirus Viral Neutralizing Antibody Titers

| NOT VACCINATED | Commercial MLV<sup>a,b</sup> | Experimental MLV<sup>b</sup> | Commercial Inactivated<sup>c</sup> | Experimental Inactivated<sup>c</sup> |
|----------------|------------------------------|-------------------------------|-----------------------------------|-----------------------------------|
| 1:32<sup>d,14e</sup> | 1:501<sup>12</sup> | 1:204,800<sup>8</sup> | 1:2896<sup>2</sup> | 1:1024<sup>14</sup> |
| 1:86<sup>e</sup> | 1:870<sup>13</sup> | 1:360,205<sup>27</sup> | 1:1950<sup>35</sup> | 1:2560<sup>17</sup> |
| 1:100<sup>19</sup> | 1:2807<sup>20</sup> | 1:678,828<sup>18</sup> | 1:288<sup>4</sup> | 1:4467<sup>38</sup> |
| 1:160–1:2560<sup>7</sup> | 1:3775<sup>27</sup> | 1:4598<sup>4</sup> | 1:13,004<sup>4</sup> | 1:20,452<sup>19</sup> |
| 1:229<sup>35</sup> | 1:4096<sup>4</sup> | 1:4598<sup>4</sup> | 1:13,004<sup>4</sup> | 1:32,768<sup>4</sup> |
| 1:320<sup>17,19</sup> | 1:4395<sup>18</sup> | 1:204,800–1:678,822 | 1:2,869 | 1:1,024–1:32,768 |
| 1:340<sup>12</sup> | 1:870<sup>13</sup> | 1:360,205<sup>27</sup> | 1:1950<sup>35</sup> | 1:2560<sup>17</sup> |
| 1:512<sup>13</sup> | 1:4096<sup>4</sup> | 1:4598<sup>4</sup> | 1:13,004<sup>4</sup> | 1:20,452<sup>19</sup> |
| 1:645<sup>34</sup> | 1:4395<sup>18</sup> | 1:204,800–1:678,822 | 1:2,869 | 1:1,024–1:32,768 |
| 1:813<sup>4</sup> | 1:4395<sup>18</sup> | 1:204,800–1:678,822 | 1:2,869 | 1:1,024–1:32,768 |
| 1:1613<sup>20</sup> | 1:4395<sup>18</sup> | 1:204,800–1:678,822 | 1:2,869 | 1:1,024–1:32,768 |
| 1:2431<sup>27</sup> | 1:4395<sup>18</sup> | 1:204,800–1:678,822 | 1:2,869 | 1:1,024–1:32,768 |
| 1:2865<sup>18</sup> | 1:4395<sup>18</sup> | 1:204,800–1:678,822 | 1:2,869 | 1:1,024–1:32,768 |
| 1:200–1:3200<sup>6</sup> | 1:501–1:4,395 | 1:204,800–1:678,822 | 1:2,869 | 1:1,024–1:32,768 |

<sup>a</sup>Calf Guard (Norden Laboratories, Lincoln, NE 68521); <sup>b</sup>MLV = modified-live virus vaccine; <sup>c</sup>Scourguard 3 (K) (Norden Laboratories); <sup>d</sup>BRV VN antibody titer; <sup>e</sup>reference; <sup>f</sup>range of values reported by various investigators.
Scourguard 3 (K) Rotavirus and Coronavirus Vaccination Programs

Scourguard 3 (K) is an inactivated bovine rotavirus-coronavirus vaccine that is combined with an *E. coli* bacterin. General recommendations for use of Scourguard 3 (K) vaccine are summarized (see Table 8). Two doses of vaccine should be administered by intramuscular injection to pregnant cows and heifers at a 2-week interval. The second (immunizing) dose should be given 2 to 3 weeks before the anticipated calving date. Cows that have not calved within 40 days after administration of the immunizing dose should be revaccinated with a single dose. A single annual booster dose should be administered, 2 to 3 weeks prior to each subsequent calving.

This vaccine has a disadvantage in that calves that do not consume adequate quantities of colostrum shortly after birth may not be protected. Newborn calves should be closely observed. Those that do not suckle vigorously within 2 hours after birth should be hand fed or tube fed with 50 to 80 ml/kg body weight of fresh or frozen colostrum.33,34 Dairy calves raised on fresh cow's milk are dramatically less susceptible to neonatal enteric disease than those raised on milk replacers (which do not contain lactoglobulins).13,26,33 Continuous feeding of fresh, frozen, or fermented colostrum from vaccinated cows throughout the first 2 to 4 weeks of life, is a highly effective means of preventing rotaviral and coronaviral infections in dairy calves.3,7,13,14,18 High-titered colostrum, resulting from vaccination with experimental vaccines, can be preventative when mixed with milk and fed in concentrations as low as 1%.18 Colostral BRV VN antibody titers achieved with commercial vaccines (see Table 24) should permit successful utilization of colostrum: milk mixtures containing 25 to 50% colostrum.

Calf Guard Rotavirus and Coronavirus Vaccination Programs

Calf Guard is a MLV rotavirus and coronavirus combination vaccine that is recommended by the manufacturer for administration either to pregnant heifers and cows or to newborn calves but not to both. General recommendations for use of this vaccine in calves and in cows and heifers are summarized (see Table 8).

Calves

Use in calves was previously discussed, under General Considerations.

Cows and Heifers

Two doses of vaccine should be administered by intramuscular injection at a 3- to 6-week interval. The second dose should be administered within 30 days of calving. Cows that do not calve during the first 60 days of the calving season should be given a booster vaccination. An identical regimen is recommended during subsequent pregnancies.

This vaccine does not produce milk and colostral VN antibody titers that are as high and as persistent as those resulting from vaccination with Scourguard 3 (K), mainly because it is relatively ineffective.
for boosting humoral and colostral antibody titers of seropositive cows\textsuperscript{2-4,12,13,20,27,28}, consequently, it cannot be recommended for this use.

REFERENCES

1. Torres-Medina A, Schlafer DH, Mebus CA: Rotaviral and coronaviral diarrhea. Vet Clin North Am [Food Anim Pract] 1:471–493, 1985
2. Sharpee RL, Nelson LD, Świeszkowski TC, et al: Enhancement of lactogenic immunity in cattle against rotavirus, coronavirus, and \textit{Escherichia coli} K99 by vaccination with an inactivated and adjuvanted combination vaccine. Dublin, Proc 14th Wrld Congr Dis Cattle, 1:398–401, 1986
3. Saif LJ, Smith KL: Enteric viral infections of calves and passive immunity. J Dairy Sci 68:206–228, 1985
4. Crouch CF: Vaccination against enteric rota and coronaviruses in cattle and pigs: Enhancement of lactogenic immunity. Vaccine 3:284–291, 1985
5. Mebus CE: Bovine rotavirus and calf coronavirus diarrhea. In Howard JL (ed): Current Veterinary Therapy — Food Animal Practice 2. Philadelphia, WB Saunders, 1986, pp 492–493
6. Van Zaane R, Ijzerman J, DeLeeuw PW: Intestinal antibody response after vaccination and infection with rotavirus of calves fed colostrum with or without rotavirus antibody. Vet Immunol Immunopathol 11:45–63, 1986
7. Wood GN, Jones J, Bridger J: Levels of colostral antibodies against neonatal calf diarrhea virus. Vet Rec 97:148–149, 1975
8. Archambault D, Morin G, Elazhary Y, et al: Immune response of pregnant heifers and cows to bovine rotavirus inoculation and passive protection to rotavirus infection in newborn calves fed colostral antibodies or colostral lymphocytes. Am J Vet Res 49:1084–1091, 1988
9. Thurber ET, Bass EP, Beckenhauer WH: Field trial evaluation of a reo-coronavirus calf diarrhea vaccine. Can J Comp Med 41:131–136, 1977
10. Blackmer PE: A practitioner’s experience with experimental reo-coronavirus calf diarrhea vaccine. Proc 8th Annu Conv, Am Assoc Bov Pract, Atlanta, pp 22–24, Dec 10–13, 1975
11. Hancock DD, Saif LJ, Bohl EH, et al: Evaluation of response to field use of a commercial oral rotavirus-coronavirus vaccine in 10 Ohio dairy herds. Proc 62nd Ann Mtg, Conf Res Wrkrs Anim Dis: 43, 1981
12. Waltner-Toews D, Martin SW, Meek AH, et al: A field trial to evaluate the efficacy of a combined rotavirus-coronavirus/\textit{Escherichia coli} vaccine in dairy cattle. Can J Comp Med 49:1–9, 1985
13. Burki F, Mostl K, Spiegl E, et al: Reduction of rotavirus, coronavirus, and \textit{E. coli}–associated calf diarrheas in a large-size dairy herd by means of dam vaccination with a triple vaccine. J Vet Med B 33:241–252, 1986
14. Castrucci G, Frigeri F, Ferrari M, et al: The efficacy of colostrum from cows vaccinated with rotavirus in protecting calves to experimentally induced rotavirus infection. Comp Immunol Microbiol Infect Dis 7:11–18, 1984
15. Acres SD, Babiuk LA: Studies on rotaviral antibody in bovine serum and lacteal secretions using radioimmunoassay. J Am Vet Med Assoc 173:555–559, 1978
16. Besser TE, Gay CC, McGuire TC, et al: Passive immunity to bovine rotavirus infection associated with transfer of serum antibody into the intestinal lumen. J Virol 62:2238–2242, 1988
17. Snodgrass DR, Stewart J, Taylor J, et al: Diarrhea in dairy calves reduced by feeding colostrum from cows vaccinated with rotavirus. Res Vet Sci 32:70–73, 1982
18. Saif LJ, Redman DR, Smith KL, et al: Passive immunity to bovine rotavirus in newborn calves fed colostrum supplements from immunized or non-immunized cows. Infect Immun 41:1118–1131, 1983
19. Snodgrass DR, Fahey KJ, Wells PW, et al: Passive immunity in calf rotavirus infections: Maternal vaccination increases and prolongs immunoglobulin G1 antibody secretion in milk. Infect Immun 28:344–349, 1980
20. Myers LL, Snodgrass DR: Colostral and milk antibody titers in cows vaccinated with a modified live rotavirus-coronavirus vaccine. J Am Vet Med Assoc 181:486–488, 1982
21. Hudson D: Rota-coronavirus vaccination of pregnant cows. Mod Vet Pract 62:626–628, 1981
22. Snodgrass DR, Ojeh CK, Campbell I, et al: Bovine rotavirus serotypes and their significance for immunization. J Clin Microbiol 20:342–346, 1984
23. Fremont FY: Vaccinations antirotavirus et anticoronavirus chez les bovins: Eléments pratiques du choix entre les vaccinations de la vache ou du veau. Rec Med Vet 159:345–349, 1983
24. Eichhorn W, Bachman PA, Baljer G, et al: Vaccination of pregnant cows with a combined rotavirus/E. coli K99 vaccine for preventing diarrhea of newborn calves. Tierarztl Umsch 37:599–600, 602–604, 1982
25. Navetat H: Méthodologie de vaccination contre les gastroenteritis à colibacille (et) à rotavirus du veau. The Netherlands, Proc 12th Wrld Congr Dis Cattle, 1982, pp 366–373
26. Van Opdenbosch E, Wellemans G: Perspectives in the prevention of viral neonatal calf diarrhea. The Netherlands, Proc 12th Wrld Congr Dis Cattle, 1982, pp 374–379
27. Saif LJ, Smith L, Landmeier BJ, et al: Immune response of pregnant cows to bovine rotavirus immunization. Am J Vet Res 45:49–58, 1984
28. Rodak L, Babiuk LA, Acres SO: Detection by radioimmunoassay and enzyme-linked immunosorbent assay of coronavirus antibodies in bovine serum and lacteal secretions. J Clin Microbiol 16:34–40, 1982
29. Woode GN, Kelso NE, Simpson TF, et al: Antigenic relationships among some bovine rotaviruses: Serum neutralization and cross-protection in gnotobiotic calves. J Clin Microbiol 18:358–364, 1983
30. Ihara T, Samejima T, Kuwahara H, et al: Isolation of new serotypes of bovine rotavirus. Arch Virol 78:145–150, 1983
31. Murakami Y, Nishioka N, Watanabe T, et al: Prolonged excretion and failure of cross-protection between distinct serotypes of bovine rotavirus. Vet Microbiol 12:7–14, 1986
32. Paul PS: Personal communications. Veterinary Medical Research Institute, Iowa State University, 1989
33. Radostits OM: Neonatal diarrhea in ruminants (calves, lambs, and kids). In Howard JL (ed): Current Veterinary Therapy—Food Animal Practice 2. Philadelphia, WB Saunders, 1986, pp 105–113
34. Lopez JW, Allen SO, Mitchell I: Rotavirus shedding in dairy calf feces and its relationship to colostrum immune transfer. J Dairy Sci 71:1286–1294, 1988
35. Snodgrass DR, Nagy LK, Sherwood D, et al: Passive immunity in calf diarrhea: Vaccination with K99 antigen of enterotoxigenic Escherichia coli and rotavirus. Infect Immun 37:586–591, 1982

**Escherichia coli Bacterins**

Enterotoxigenic strains of *E. coli* cause severe diarrheal disease in neonatal calves by colonizing the small intestinal villi, replicating to extremely large numbers (10⁸ to 10¹⁰ E. coli per gram of intestinal contents), and producing a heat-stable enterotoxin.¹ *E. coli* enterotoxin causes a net increase in secretion of fluid by small intestinal secretory (crypt) cells, which is the basis for the diarrhea, hypovolemia, dehydration, weakness, shock, hyponatremia, hypocloremia, and acidosis/hyperkalemia that can result.¹⁻³

**General Considerations**

Most *E. coli* bacterins currently marketed in the United States are formulated so as to ensure a high content of K99 pilus (fimbria for